• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Picard Medical Inc.

    1/27/26 4:05:27 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care
    Get the next $PMI alert in real time by email
    S-8 1 picardmedical_s8.htm S-8

     

    As filed with the United States Securities and Exchange Commission on January 27, 2026.

     

    Registration No: 333-         

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933

     

     

     

    Picard Medical, Inc.
    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   86-3212894
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification Number)

     

    1992 E Silverlake
    Tucson AZ
      85713
    (Address of Principal Executive Offices)   (Zip Code)

     

    Amended and Restated 2021 Equity Incentive Plan

    (Full Title of Plans)

     

     

     

    Patrick NJ Schnegelsberg

    Chief Executive Officer
    Picard Medical, Inc.

    1992 E Silverlake
    Tucson AZ, 85713

    (520) 545-1234

    (Name, address, and telephone number, including area code, of agent for service)

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    Part I

     

    INFORMATION REQUIRED IN THE

    SECTION 10(a) PROSPECTUS

     

    The documents containing information specified by Part I of Form S-8 will be sent or given to participants in the Amended and Restated 2021 Equity Incentive Plan (the “Plan”), as specified in Rule 428(b)(1) promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Commission but constitute (along with the documents incorporated by reference into this Registration Statement on Form S-8 (this “Registration Statement”) pursuant to Item 3 of Part II hereof), a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents that Picard Medical, Inc. (the “Company” or “we”) has filed with the Commission under the Securities Act and the Securities Exchange Act of 1934 (the “Exchange Act”) are incorporated by reference into this Registration Statement:

     

    ● The Company’s Prospectus filed pursuant to Rule 424(b)(4) filed with the Commission on September 2, 2025.

     

    ● The Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025, filed with the Commission on September 12, 2025 and November 14, 2025, respectively;

     

      ● The Company’s Current Reports on Form 8-K filed on September 4, 2025, September 10, 2025, October 14, 2025, October 27, 2025, November 14, 2025, November 19, 2025, November 26, 2025 (one announced entry into an unsecured promissory note and the other one announced Duffy Elmer’s presentation on the Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support), December 3, 2025, December 4, 2025, December 9, 2025, December 18, 2025, December 30, 2025, and January 13, 2026 (one published an investor presentation and the other one announced the launch of the Cruxx to MedTech Podcast, a series exploring the SynCardia Total Artificial Heart and the Emperor device); and

     

    ● The description of the Company’s common stock contained in the Company’s Registration Statement on Form 8-A filed with the Commission on August 11, 2025, including any amendment or report filed for purposes of updating the description.

     

    All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part thereof from the date of filing of such documents with the Commission. Any statement contained in a document incorporated, or deemed to be incorporated, by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such prior statement. Any statement contained in this Registration Statement shall be deemed to be modified or superseded to the extent that a statement contained in a subsequently filed document that is, or is deemed to be incorporated, by reference in this Registration Statement modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    No document or information deemed to be furnished and not filed in accordance with the rules of the Commission shall be deemed to be incorporated herein by reference unless such document or information expressly provides to the contrary.

     

    Item 4. Description of Securities

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers

     

    Subsection (a) of Section 145 of the Delaware General Corporation Law (referred to as the “DGCL”) provides that a corporation may indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.

     

    2

     

     

    Subsection (b) of Section 145 provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted under similar standards, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to be indemnified for such expenses which the court shall deem proper.

     

    Section 145 of the DGCL further provides that (i) to the extent that a former or present director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith; (ii) indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and (iii) the corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.

     

    Section 102(b)(7) of the DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or an officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or an officer, provided that such provision shall not eliminate or limit the liability of a director or an officer (i) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director or officer derived an improper personal benefit, and provided further that such provision shall not eliminate or limit the liability of an officer in any action by or in the right of the corporation.

     

    Our second amended and restated certificate of incorporation provides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and our amended and restated bylaws provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL.

     

    In addition, we entered into indemnification agreements with each of our directors and officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We intend to enter into indemnification agreements with our future directors.

     

    Item 7. Exemption from Registration Claimed

     

    Not applicable.

     

    3

     

     

    Item 8. Exhibits

     

    The exhibits filed herewith or incorporated by reference herein are set forth in the Exhibit Index filed as part of this Registration Statement.

     

    exhibit index

     

    Exhibit No.   Description
    4.1   Second Amended and Restated Certificate of Incorporation of Picard Medical, Inc. (incorporated by reference to Exhibit 3.1 filed with the Company’s Current Report on Form 8-K (File No. 001-42801) filed on September 4, 2025).
    4.2   Amended and Restated Bylaws of Picard Medical, Inc., as in effect (incorporated by reference to Exhibit 3.2 filed with the Company’s Current Report on Form 8-K (File No. 001-42801) filed on September 4, 2025).
    4.3   Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K (File No. 001-42801) filed on October 14, 2025).
    5.1   Opinion of Han Kun Law Offices LLP (filed herewith).
    23.1   Consent of Han Kun Law Offices LLP (included in Exhibit 5.1).
    23.2   Consent of MaloneBailey, LLP. (filed herewith).
    24.1   Power of Attorney (set forth on signature page).
    107   Filing Fee Table (filed herewith).

     

    Item 9. Undertakings

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    4

     

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Company has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tucson, State of Arizona on the 27th day of January, 2026.

     

    Picard Medical, Inc.  
         
    By: /s/ Patrick NJ Schnegelsberg  
    Name: Patrick NJ Schnegelsberg  
    Title: Chief Executive Officer  

     

    powers of attorney

     

    The undersigned officers and directors do hereby constitute and appoint Patrick NJ Schnegelsberg, with full power of substitution and re-substitution, as our true and lawful attorney-in-fact and agent, to do any and all acts and things in our name and behalf in our capacities as directors and officers, and to execute any and all instruments for us and in our names in the capacities indicated below, that such person may deem necessary or advisable to enable the Company to comply with the Securities Act and any rules, regulations and requirements of the Commission in connection with this Registration Statement, including specifically, but not limited to, power and authority to sign for us, any of us, in the capacities indicated below, any and all amendments hereto (including post-effective amendments); and we do hereby ratify and confirm all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             
    /s/ Patrick NJ Schnegelsberg  

    Principal Executive Officer and Director

      January 27, 2026
    Patrick NJ Schnegelsberg   (Principal Executive Officer)    
             
    /s/ Bernard Skaggs  

    Principal Financial Officer

     

    January 27, 2026

    Bernard Skaggs   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Richard Fang       January 27, 2026
    Richard Fang   Director    
             
    /s/ Sam Van        
    Sam Van   Director   January 27, 2026
             
    /s/ George Ye        
    George Ye   Director   January 27, 2026

     

    6

    Get the next $PMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMI
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Picard Medical Inc.

    S-1/A - Picard Medical, Inc. (0002030617) (Filer)

    2/3/26 10:01:11 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Picard Medical Inc.

    S-8 - Picard Medical, Inc. (0002030617) (Filer)

    1/27/26 4:05:27 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Picard Medical Inc.

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    1/13/26 4:05:25 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sindex Ssi Lending, Llc claimed ownership of 7,943,585 shares (SEC Form 3)

    3 - Picard Medical, Inc. (0002030617) (Issuer)

    11/13/25 4:15:36 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Picard Medical / SynCardia to Present Webinar on the Emperor Fully Implantable Total Artificial Heart Hosted by DeviceTalks

    TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company's fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. Schuster will review preclinical experience with SynCardia's next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data

    1/29/26 4:05:00 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard / SynCardia Featured on the Cruxx of MedTech Podcast

    TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management. Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System's / Picard Medical's

    1/13/26 9:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    SynCardia and Hydrix Enter into Development Collaboration to Advance the Emperor, SynCardia's Next Generation Total Artificial Heart

    TUCSON, Ariz., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that on January 5, 2026 SynCardia entered into a development collaboration agreement (the "Agreement") with Hydrix Services Pty Ltd ("Hydrix"), a wholly owned subsidiary of Hydrix Limited (ASX: HYD), to commence an initial development phase for SynCardia's next-generation, fully implantable Total Artificial Heart (TAH) technology, known as the Emperor. As a fully implantable TAH, Emperor would eliminate the use of an external dr

    1/12/26 8:30:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care